Ownership and insider activity for ABVC BioPharma, Inc. (ABVC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18645 | $256925 | $40044 | $144295 | $5.0M | $5.8M | $1.4M | $716780 | $863815 | $681480 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $108147 | $75797 | $79312 | $64736 | $64354 |
| Receivables | 0 | $2.5M | $14639 | $640526 | $999402 | $426091 | $1.4M | $759566 | $1.2M | $763388 |
| Inventory | 0 | $199708 | $1318 | -$476960 | 0 | $25975 | 0 | 0 | 0 | 0 |
| Total Current Assets | $18645 | $760973 | $96273 | $878238 | $6.2M | $7.7M | $3.0M | $1.7M | $2.2M | $2.5M |
| Property, Plant & Equipment | 0 | $570576 | $510066 | $1.0M | $2.3M | $2.0M | $1.7M | $1.4M | $1.2M | $14.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $18645 | $6.6M | $96273 | $6.9M | $14.8M | $13.7M | $10.9M | $7.8M | $7.5M | $21.1M |
| Accounts Payable | 0 | 0 | $14639 | $23995 | $23044 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | $1.1M | $550000 | $4.0M | $2.7M | $1.9M | $2.6M | $2.4M | $3.0M | $1.9M |
| Total Current Liabilities | $6.5M | $4.1M | $5.6M | $6.8M | $4.8M | $3.7M | $5.5M | $6.1M | $6.6M | $6.2M |
| Long-term Debt | 0 | 0 | $250000 | 0 | $2.6M | 0 | 0 | 0 | 0 | $1.6M |
| Total Liabilities | $6.5M | $4.1M | $5.8M | $7.1M | $8.9M | $4.8M | $6.3M | $6.5M | $6.8M | $7.8M |
| Retained Earnings | -$11.5M | -$10.0M | -$19.9M | -$15.9M | -$25.6M | -$38.5M | -$54.9M | -$64.0M | -$68.9M | -$76.9M |
| Total Equity | -$6.5M | $1.7M | -$5.7M | -$150964 | $6.6M | $8.8M | $4.5M | $1.6M | $1.2M | $11.1M |
| Total Debt | 0 | $1.2M | $800000 | $4.6M | $6.8M | $3.3M | $3.4M | $2.8M | $3.2M | $3.5M |
| Net Debt | -$18645 | $969197 | $759956 | $4.4M | $1.8M | -$2.6M | $1.9M | $2.0M | $2.3M | $2.7M |
| Working Capital | -$6.5M | -$3.3M | -$5.5M | -$5.9M | $1.3M | $4.0M | -$2.6M | -$4.4M | -$4.4M | -$3.7M |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 0.07 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.61 |
Profitability
| Return on Equity | -71.17% |
| Return on Invested Capital | -42.64% |
| Return on Assets | -37.55% |
| Gross Margin | 100.00% |
| Operating Margin | 918.55% |
| Net Margin | 992.85% |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks